smallpox

Biopharma Chimerix has landed a contract worth as much as $680 million with the federal government for its smallpox treatment TEMBEXA, which was approved by the FDA.

Chimerix has agreed to sell its smallpox countermeasure to Emergent BioSolutions in a deal worth as much as $337 million.

The U.S. Food and Drug Administration has just granted Chimerix marketing approval for the tablet and oral suspension formulations of its smallpox treatment TEMBEXA (brincidofovir).

Chimerix, a Durham-based biopharmaceutical company that’s developing medicines to treat cancer and other diseases, has received good regulatory news for its potential antiviral treatment for smallpox.

The Durham-based biopharmaceutical company, which develops antiviral medicines for unmet medical needs, this week announced it had received clearance from the FDA for a rolling submission of its New Drug Application for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox.

Chimerix has struck a licensing and development deal for its experimental antiviral drug brincidofovir  with SymBio Pharmaceuticals in a deal that could be worth as much as $180 million plus royalties.